Ribavirin (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ribavirin" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

10nih.gov

4^th place

8^th place

9doi.org

2^nd place

5^th place

4web.archive.org

1^st place

2^nd place

2oxfordjournals.org

1,389^th place

362^nd place

1tga.gov.au

3,984^th place

2,156^th place

1termania.net

low place

34^th place

1webmd.com

1,169^th place

312^th place

1medscape.com

719^th place

152^nd place

1easl.eu

low place

1europa.eu

68^th place

28^th place

1rki.de

4,845^th place

low place

1wiley.com

222^nd place

163^rd place

1uptodate.com

3,771^st place

1,626^th place

doi.org

Paeshuyse, J; Dallmeier, K; Neyts, J (december 2011). »Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action«. Current Opinion in Virology. 1 (6): 590–8. doi:10.1086/657315. PMID 22440916.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Flori, N; Funakoshi, N; Duny, Y; Valats, JC; Bismuth, M; Christophorou, D; Daurès, JP; Blanc, P (Marec 2013). »Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis«. Drugs. 73 (3): 263–277. doi:10.1007/s40265-013-0027-1. PMID 23436591.
Druyts, E; Thorlund, K; Wu, P; Kanters, S; Yaya, S; Cooper, CL; Mills, EJ (april 2013). »Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis«. Clinical Infectious Diseases. 56 (7): 961–7. doi:10.1093/cid/cis1031. PMID 23243171.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Zeuzem, S; Poordad, F (Julij 2010). »Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response«. Current Medical Research and Opinion. 26 (7): 1733–1743. doi:10.1185/03007995.2010.487038. PMID 20482242.
Ascioglu, S; Leblebicioglu, H; Vahaboglu, H; Chan, KA (Junij 2011). »Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis« (PDF). The Journal of Antimicrobial Chemotherapy. 66 (6): 1215–1222. doi:10.1093/jac/dkr136. PMID 21482564.
Bausch, DG; Hadi, CM; Khan, SH; Lertora, JJ (15. december 2010). »Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever« (PDF). Clinical Infectious Diseases. 51 (12): 1435–1441. doi:10.1086/657315. PMID 21058912.
Soares-Weiser, K; Thomas, S; Thomson, G; Garner, P (13. julij 2010). »Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis«. BMC Infectious Diseases. 10: 207. doi:10.1186/1471-2334-10-207. PMC 2912908. PMID 20626907.
Ventre, K; Randolph, AG (24. januar 2007). »Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children« (PDF). The Cochrane Database of Systematic Reviews (1): CD000181. doi:10.1002/14651858.CD000181.pub3. PMID 17253446. Pridobljeno 15. aprila 2014.{{navedi časopis}}: Vzdrževanje CS1: url-status (povezava)
Hemachudha, T; Ugolini, G; Wacharapluesadee, S; Sungkarat, W; Shuangshoti, S; Laothamatas, J (Maj 2013). »Human rabies: neuropathogenesis, diagnosis, and management«. Lancet Neurology. 12 (5): 498–513. doi:10.1016/S1474-4422(13)70038-3. PMID 23602163.

easl.eu

files.easl.eu

http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-c-summary/index.html#p=2 Arhivirano 2014-04-19 na Wayback Machine., vpogled: 18. 4. 2014.

europa.eu

ema.europa.eu

Povzetek glavnih značilnosti zdravila Ribavirin Teva, http://www.ema.europa.eu/docs/sl_SI/document_library/EPAR_-_Product_Information/human/001018/WC500056547.pdf Arhivirano 2014-04-19 na Wayback Machine., vpogled: 18. 4. 2014.

medscape.com

reference.medscape.com

»Rebetol, Ribasphere (ribavirin) dosing, indications, interactions, adverse effects, and more«. Medscape Reference. WebMD. Pridobljeno 23. februarja 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Paeshuyse, J; Dallmeier, K; Neyts, J (december 2011). »Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action«. Current Opinion in Virology. 1 (6): 590–8. doi:10.1086/657315. PMID 22440916.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Flori, N; Funakoshi, N; Duny, Y; Valats, JC; Bismuth, M; Christophorou, D; Daurès, JP; Blanc, P (Marec 2013). »Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis«. Drugs. 73 (3): 263–277. doi:10.1007/s40265-013-0027-1. PMID 23436591.
Druyts, E; Thorlund, K; Wu, P; Kanters, S; Yaya, S; Cooper, CL; Mills, EJ (april 2013). »Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis«. Clinical Infectious Diseases. 56 (7): 961–7. doi:10.1093/cid/cis1031. PMID 23243171.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Zeuzem, S; Poordad, F (Julij 2010). »Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response«. Current Medical Research and Opinion. 26 (7): 1733–1743. doi:10.1185/03007995.2010.487038. PMID 20482242.
Ascioglu, S; Leblebicioglu, H; Vahaboglu, H; Chan, KA (Junij 2011). »Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis« (PDF). The Journal of Antimicrobial Chemotherapy. 66 (6): 1215–1222. doi:10.1093/jac/dkr136. PMID 21482564.
Bausch, DG; Hadi, CM; Khan, SH; Lertora, JJ (15. december 2010). »Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever« (PDF). Clinical Infectious Diseases. 51 (12): 1435–1441. doi:10.1086/657315. PMID 21058912.
Soares-Weiser, K; Thomas, S; Thomson, G; Garner, P (13. julij 2010). »Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis«. BMC Infectious Diseases. 10: 207. doi:10.1186/1471-2334-10-207. PMC 2912908. PMID 20626907.
Ventre, K; Randolph, AG (24. januar 2007). »Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children« (PDF). The Cochrane Database of Systematic Reviews (1): CD000181. doi:10.1002/14651858.CD000181.pub3. PMID 17253446. Pridobljeno 15. aprila 2014.{{navedi časopis}}: Vzdrževanje CS1: url-status (povezava)
Hemachudha, T; Ugolini, G; Wacharapluesadee, S; Sungkarat, W; Shuangshoti, S; Laothamatas, J (Maj 2013). »Human rabies: neuropathogenesis, diagnosis, and management«. Lancet Neurology. 12 (5): 498–513. doi:10.1016/S1474-4422(13)70038-3. PMID 23602163.

ncbi.nlm.nih.gov

Soares-Weiser, K; Thomas, S; Thomson, G; Garner, P (13. julij 2010). »Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis«. BMC Infectious Diseases. 10: 207. doi:10.1186/1471-2334-10-207. PMC 2912908. PMID 20626907.

oxfordjournals.org

jac.oxfordjournals.org

Ascioglu, S; Leblebicioglu, H; Vahaboglu, H; Chan, KA (Junij 2011). »Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis« (PDF). The Journal of Antimicrobial Chemotherapy. 66 (6): 1215–1222. doi:10.1093/jac/dkr136. PMID 21482564.

cid.oxfordjournals.org

Bausch, DG; Hadi, CM; Khan, SH; Lertora, JJ (15. december 2010). »Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever« (PDF). Clinical Infectious Diseases. 51 (12): 1435–1441. doi:10.1086/657315. PMID 21058912.

rki.de

Steckbriefe seltener und importierter Infektionskrankheiten [Characteristics of rare and imported infectious diseases] (PDF). Berlin: Robert Koch Institute. 2006. ISBN 3-89606-095-3. Arhivirano iz prvotnega spletišča (PDF) dne 29. septembra 2011. Pridobljeno 18. aprila 2014.

termania.net

http://www.termania.net/slovarji/slovenski-medicinski-slovar/5537005/ribavirin?query=ribavirin, SLovenski medicinski e-slovar, vpogled: 18. 4. 2014.

tga.gov.au

ebs.tga.gov.au

»PRODUCT INFORMATION REBETOL® (RIBAVIRIN) CAPSULES« (PDF). TGA eBusiness Services. Merck Sharp & Dohme (Australia) Pty Limited. 29. april 2013. Pridobljeno 23. februarja 2014.

uptodate.com

http://www.uptodate.com/contents/mechanism-of-action-and-efficacy-of-ribavirin-for-the-treatment-of-chronic-hepatitis-c-virus-infection Arhivirano 2014-04-19 na Wayback Machine., vpogled: 18. 4. 2014.

web.archive.org

http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-c-summary/index.html#p=2 Arhivirano 2014-04-19 na Wayback Machine., vpogled: 18. 4. 2014.
Povzetek glavnih značilnosti zdravila Ribavirin Teva, http://www.ema.europa.eu/docs/sl_SI/document_library/EPAR_-_Product_Information/human/001018/WC500056547.pdf Arhivirano 2014-04-19 na Wayback Machine., vpogled: 18. 4. 2014.
Steckbriefe seltener und importierter Infektionskrankheiten [Characteristics of rare and imported infectious diseases] (PDF). Berlin: Robert Koch Institute. 2006. ISBN 3-89606-095-3. Arhivirano iz prvotnega spletišča (PDF) dne 29. septembra 2011. Pridobljeno 18. aprila 2014.
http://www.uptodate.com/contents/mechanism-of-action-and-efficacy-of-ribavirin-for-the-treatment-of-chronic-hepatitis-c-virus-infection Arhivirano 2014-04-19 na Wayback Machine., vpogled: 18. 4. 2014.

webmd.com

http://www.webmd.com/drugs/mono-1279-RIBAVIRIN+TABLET+-+ORAL.aspx?drugid=21961&drugname=ribavirin+Oral, vpogled: 18. 4. 2014.

wiley.com

onlinelibrary.wiley.com

Ventre, K; Randolph, AG (24. januar 2007). »Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children« (PDF). The Cochrane Database of Systematic Reviews (1): CD000181. doi:10.1002/14651858.CD000181.pub3. PMID 17253446. Pridobljeno 15. aprila 2014.{{navedi časopis}}: Vzdrževanje CS1: url-status (povezava)